This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / ASCO 2026 Oncology Research Presentations
Tech medical conference

ASCO 2026 Oncology Research Presentations

Analysis based on 33 articles · First reported May 25, 2026 · Last updated Jun 08, 2026

Sentiment
70
Attention
7
Articles
33
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The presentations of new clinical data and research at the ASCO Annual Meeting are expected to positively impact the pharmaceutical and biotechnology sectors. Companies like Jiangsu Hengrui, Menarini Group, and Kura Oncology, which presented promising results for their oncology pipelines, could see increased investor confidence and potential for future drug approvals. Dassault Systèmes — Medidata Solutions's research on trial optimization may lead to more efficient drug development, benefiting the broader industry.

Pharmaceuticals Biotechnology Healthcare
Event Summary

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, served as a crucial platform for presenting advancements in cancer research and clinical development. Jiangsu Hengrui showcased over 90 studies, highlighting its extensive oncology pipeline across various cancer types. Menarini Group and its subsidiary AnBogen Therapeutics, Inc. announced new data for elacestrant and tagraxofusp, with Karyopharm Therapeutics also presenting on selinexor. Kura Oncology presented new clinical and translational data supporting darlifarnib as a foundational combination platform for KRAS-mutant cancers. Additionally, Dassault Systèmes — Medidata Solutions presented research on optimizing oncology trial protocols and evaluating tocilizumab's efficacy for CAR T-induced Cytokine Release Syndrome, leveraging AI and clinical trial data. These presentations underscore ongoing innovation in cancer treatment and clinical trial methodologies.

Entities Involved
ngo
American Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO) is the host of the annual meeting where new cancer research and clinical development advances are presented, making it a central entity for this event.
Importance 100.0 Sentiment 70.0
stock
Jiangsu Hengrui
Jiangsu Hengrui presented over 90 studies at the ASCO Annual Meeting, showcasing its extensive oncology pipeline and innovative therapies, which could positively impact its market position and future drug approvals.
Importance 95.0 Sentiment 75.0
oth
Ivonescimab
Ivonescimab is a core first-in-class bispecific antibody developed by Akeso, with Phase III overall survival results from the HARMONi-6 study being a pivotal highlight at ASCO 2026. Its positive data in various cancers could lead to significant market impact.
Importance 90.0 Sentiment 70.0
stock
Kura Oncology
Kura Oncology highlighted new clinical and translational data for darlifarnib as a potential foundational combination platform for KRAS-mutant cancers, reinforcing its position in precision oncology and potentially expanding its pipeline.
Importance 90.0 Sentiment 75.0
oth
Cadonilimab
Cadonilimab is another core first-in-class bispecific antibody from Akeso's portfolio, with regimens being presented for various tumor types at ASCO 2026, indicating its potential clinical benefits.
Importance 80.0 Sentiment 65.0
stock
Akeso
Akeso announced that over 40 clinical studies of its oncology portfolio, including data on cadonilimab and ivonescimab, were presented at the 2026 ASCO Annual Meeting, with one Late-Breaking Abstract selected for a Plenary Session.
Importance 80.0 Sentiment 65.0
priv
Menarini Group
Menarini Group, along with its subsidiary AnBogen Therapeutics, Inc., presented new data related to elacestrant and tagraxofusp at the ASCO Annual Meeting, highlighting its commitment to oncology treatments and potentially boosting its product portfolio.
Importance 80.0 Sentiment 70.0
stock
Karyopharm Therapeutics
Karyopharm Therapeutics, a partner of AnBogen Therapeutics, Inc., presented late-breaking oral presentation data from the SENTRY trial of selinexor in myelofibrosis, which could enhance its product's market adoption.
Importance 70.0 Sentiment 65.0
priv
AnBogen Therapeutics
AnBogen Therapeutics, a wholly-owned subsidiary of the Menarini Group, announced new data related to elacestrant and tagraxofusp at the 2026 ASCO Annual Meeting, and its partner Karyopharm Therapeutics presented data on selinexor.
Importance 70.0 Sentiment 65.0
subs
Dassault Systèmes — Medidata Solutions
Dassault Systèmes — Medidata Solutions presented research on oncology protocol optimization and CAR T efficacy, leveraging AI and clinical trial data to improve trial design and patient outcomes, which could enhance its reputation as a clinical trial solutions provider.
Importance 60.0 Sentiment 60.0
per
Naveen Pemmaraju
Naveen Pemmaraju, MD, Professor at The University of Texas MD Anderson Cancer Center, presented new phase 2 tagraxofusp combination data in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Importance 50.0 Sentiment 60.0
oth
Ligufalimab
Ligufalimab is a novel therapeutic antibody from Akeso, a next-generation CD47 monoclonal antibody, also featured in presentations at ASCO 2026.
Importance 50.0 Sentiment 60.0
per
Troy E. Wilson
Troy E. Wilson, President and CEO of Kura Oncology, reinforced the belief that darlifarnib has the potential to become a foundational combination backbone for molecularly defined cancers.
Importance 40.0 Sentiment 60.0
per
Mollie Leoni
Mollie Leoni, Chief Medical Officer of Kura Oncology, stated that darlifarnib may have broad applicability across expanding classes of therapies, creating opportunities for improved patient outcomes and future collaborations.
Importance 40.0 Sentiment 60.0
per
Shun Lu
Professor Shun Lu from Shanghai Chest Hospital is the presenter for the Plenary Session on ivonescimab's HARMONi-6 study results.
Importance 40.0 Sentiment 0.0
+ 28 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.